↓ Skip to main content

Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery

Overview of attention for article published in Breast Cancer Research and Treatment, November 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

blogs
1 blog
twitter
2 X users

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
55 Mendeley
Title
Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery
Published in
Breast Cancer Research and Treatment, November 2013
DOI 10.1007/s10549-013-2782-9
Pubmed ID
Authors

Michael D. Alvarado, Jay Conolly, Catherine Park, Theadora Sakata, Aron J. Mohan, Brittany L. Harrison, Mitchell Hayes, Laura J. Esserman, Elissa M. Ozanne

Abstract

The TARGIT-A Trial is an international randomized, prospective trial comparing intraoperative radiotherapy (IORT) for equivalence to external beam radiotherapy (EBRT) following lumpectomy for invasive breast cancer in selected low-risk patients; early results suggest that outcomes are similar. In addition to effectiveness data and cost considerations, the preferences of patients should help inform practice. This study was undertaken to explore and quantify preference in choosing between IORT and the current standard, EBRT. Eligible subjects were current or past candidates for breast-conserving surgery and radiation being seen at the University of California, San Francisco Breast Care Center. A trade-off technique varying the risk of local recurrence for IORT was used to quantify any additional accepted risk that these patients would accept to receive either treatment. Patients were first presented with a slideshow comparing EBRT with the experimental IORT option before being asked their preferences given hypothetical 10-year local recurrence risks. Patients were then given a questionnaire on demographic, social and clinical factors. Data from 81 patients were analyzed. The median additional accepted risk to have IORT was 2.3 % (-9 to 39 %), mean 3.2 %. Only 7 patients chose to accept additional risk for EBRT; 22 accepted IORT at no additional risk; and the remaining 52 chose IORT with some additional risk. Patients weigh trade-offs of risks and benefits when presented with medical treatment choices. Our results show that the majority of breast cancer patients will accept a small increment of local risk for a simpler delivery of radiation. Further studies that incorporate outcome and side effect data from the TARGIT-A trial clarify the expected consequences of a local recurrence, and include an expanded range of radiation options that could help guide clinical decision making in this area.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 1 2%
Canada 1 2%
Unknown 53 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 15%
Other 6 11%
Researcher 6 11%
Student > Ph. D. Student 4 7%
Student > Postgraduate 3 5%
Other 9 16%
Unknown 19 35%
Readers by discipline Count As %
Medicine and Dentistry 19 35%
Psychology 3 5%
Social Sciences 2 4%
Nursing and Health Professions 2 4%
Economics, Econometrics and Finance 2 4%
Other 6 11%
Unknown 21 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2020.
All research outputs
#2,453,497
of 22,736,112 outputs
Outputs from Breast Cancer Research and Treatment
#366
of 4,650 outputs
Outputs of similar age
#29,902
of 306,491 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#9
of 71 outputs
Altmetric has tracked 22,736,112 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,650 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,491 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.